Quiet day — ClinicalTrials.gov has not yet posted any updates dated 2026-05-29 (registry-wide totalCount=0); no new in-scope material signals. — 0 trials with material updates.

Competitive Intelligence · Obesity and Type 2 Diabetes

Friday, May 29, 2026

Quiet day — ClinicalTrials.gov has not yet posted any updates dated 2026-05-29 (registry-wide totalCount=0); no new in-scope material signals.

No material signals today — this digest would normally be suppressed.

Key Signals · 0 trials updated

  • All in-scope hits inside the window `RANGE[2026-05-28,2026-05-29]` carry `LastUpdatePostDate=2026-05-28` and were classified yesterday — chiefly Novo Nordisk's IcoSema COMBINE 4 Phase 3 → COMPLETED (NCT06269107), already counted in the 2026-05-28 digest.
  • Sanity-check counts confirm zero is real, not a query bug: `RANGE[2026-05-29,2026-05-29]` = 0 studies registry-wide (no condition/sponsor filters); `RANGE[2026-05-28,2026-05-28]` = 982. The 2026-05-29 daily batch simply has not posted yet.
  • Coverage is contiguous with the prior run (2026-05-28 covered through that date); no catch-up scan needed.

No new material signals — 2026-05-29

Three query passes were run against AREA[LastUpdatePostDate]RANGE[2026-05-28,2026-05-29]:

1. Condition class obesity/T2D, Phase 2/3 → 13 hits, all with LastUpdatePostDate=2026-05-28 (yesterday).

2. Priority sponsors (Novo, Lilly, Pfizer) any phase via condition → 3 hits, all 2026-05-28.

3. Tracked sponsors (AZ, BI, Amgen, Roche, Rhythm, Altimmune, Structure, Viking, Hanmi, Zealand) Phase 2/3 → 0.

Why zero is real, not a query artifact

Registry-wide counts (no condition/sponsor filters):

  • RANGE[2026-05-29,2026-05-29] → 0 studies
  • RANGE[2026-05-28,2026-05-28] → 982 studies

ClinicalTrials.gov has not yet posted any LastUpdatePostDate=2026-05-29 records — the daily posting batch evidently hasn't run yet (the prior business day, 2026-05-28, was a normal-volume day at 982 updates). This is structural, not a broken pass.

Carryover (already reported, not re-counted)

All 13 condition-pass hits and 3 priority-sponsor hits are LastUpdatePostDate=2026-05-28 items captured in yesterday's report-2026-05-28.json — chiefly:

  • NCT06269107 — Novo IcoSema COMBINE 4 Phase 3 → COMPLETED (yesterday's headline; results not yet posted).
  • NCT07282613 — Novo CagriSema pediatric T2D Phase 3 (admin update, no identifiable delta).
  • Kailera KAI-7535 (NCT07497880) and KAI-9531 (NCT07284901) — scope-hygiene proposals stand from yesterday.
  • Out-of-scope: Pfizer ponsegromab (cachexia), Regor RGT001-075, Corxel/DIAO Chinese assets, academic studies, NIDDK alpha-lipoic+mirabegron, Cairo bariatric procedure.

Coverage continuity

Prior run (2026-05-28) covered window RANGE[2026-05-27,2026-05-28]. Today's window RANGE[2026-05-28,2026-05-29] overlaps on 2026-05-28 (carryover only) and is otherwise empty. No coverage gap. If a 2026-05-29 batch posts later in the day, the next run's window (2026-05-29 → 2026-05-30) will capture it.

Scope hygiene — no change

Proposals from prior runs remain open and unincorporated by the user:

  • MET233 (Pfizer/Metsera amylin analog) — surfaced 2026-05-27.
  • Kailera sponsor + KAI-7535 + KAI-9531 — surfaced 2026-05-28.

No new scope-hygiene candidates surfaced today.

Generated by Claude Code + ClinicalTrials.gov MCP · clinicaltrials.gov
Rendered: 2026-05-29T13:08:58.233Z · prompt f8ca428e6d80